Bennett Brad C, Wan Qun, Ahmad Md Faiz, Langan Paul, Dealwis Chris G
Department of Pharmacology, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-4965, USA.
J Struct Biol. 2009 May;166(2):162-71. doi: 10.1016/j.jsb.2009.01.001.
For reasons of bioterrorism and drug resistance, it is imperative to identify and develop new molecular points of intervention against anthrax. Dihydrofolate reductase (DHFR) is a highly conserved enzyme and an established target in a number of species for a variety of chemotherapeutic programs. Recently, the crystal structure of Bacillus anthracis DHFR (baDHFR) in complex with methotrexate (MTX) was determined and, based on the structure, proposals were made for drug design strategies directed against the substrate-binding site. However, little is gleaned about the binding site for NADPH, the cofactor responsible for hydride transfer in the catalytic mechanism. In the present study, X-ray crystallography at 100 K was used to determine the structure of baDHFR in complex with MTX and NADPH. Although the NADPH binding mode is nearly identical to that seen in other DHFR ternary complex structures, the adenine moiety adopts an off-plane tilt of nearly 90 degrees and this orientation is stabilized by hydrogen bonds to functionally conserved Arg residues. A comparison of the binding site, focusing on this region, between baDHFR and the human enzyme is discussed, with an aim at designing species-selective therapeutics. Indeed, the ternary model, refined to 2.3 A resolution, provides an accurate template for testing the feasibility of identifying dual-site inhibitors, compounds that target both the substrate and cofactor-binding site. With the ternary model in hand, using in silico methods, several compounds were identified which could potentially form key bonding contacts in the substrate and cofactor-binding sites. Ultimately, two structurally distinct compounds were verified that inhibit baDHFR at low microM concentrations. The apparent Kd for one of these, (2-(3-(2-(hydroxyimino)-2-(pyridine-4-yl)-6,7-dimethylquinoxalin-2-yl)-1-(pyridine-4-yl)ethanone oxime), was measured by fluorescence spectroscopy to be 5.3 microM.
出于生物恐怖主义和耐药性的原因,识别和开发针对炭疽的新分子干预靶点势在必行。二氢叶酸还原酶(DHFR)是一种高度保守的酶,在许多物种中是多种化疗方案的既定靶点。最近,确定了炭疽芽孢杆菌DHFR(baDHFR)与甲氨蝶呤(MTX)复合物的晶体结构,并基于该结构提出了针对底物结合位点的药物设计策略。然而,关于NADPH的结合位点了解甚少,NADPH是催化机制中负责氢化物转移的辅因子。在本研究中,利用100K下的X射线晶体学确定了baDHFR与MTX和NADPH复合物的结构。尽管NADPH的结合模式与其他DHFR三元复合物结构中所见的模式几乎相同,但腺嘌呤部分采用了近90度的面外倾斜,并且这种取向通过与功能保守的精氨酸残基的氢键得以稳定。讨论了baDHFR与人酶之间结合位点的比较,重点关注该区域,旨在设计物种选择性疗法。实际上,精修至2.3埃分辨率的三元模型为测试识别双位点抑制剂(即同时靶向底物和辅因子结合位点的化合物)的可行性提供了准确模板。有了三元模型,利用计算机模拟方法,鉴定了几种可能在底物和辅因子结合位点形成关键键合接触的化合物。最终,验证了两种结构不同的化合物在低微摩尔浓度下抑制baDHFR。其中一种化合物(2-(3-(2-(羟基肟基)-2-(吡啶-4-基)-6,7-二甲基喹喔啉-2-基)-1-(吡啶-4-基)乙酮肟)的表观解离常数通过荧光光谱法测得为5.3微摩尔。